The side effect profile mirrors what you'd expect from GLP-1-based drugs: Nausea, particularly when starting or increasing the dose Diarrhoea and, less often, constipation Reduced appetite (which is, of course, partly the point) Tiredness in the first few weeks Occasional vomiting at higher doses In the Phase 2 trials, most side effects were rated mild to moderate and tended to settle as the body adjusted
When both insulin and oral agents are used, assign only Z79.4
Hair greying is closely tied to the NMN and the ageing process, along with factors like stress, ageing, and hair greying happening together over time
It is notable that the total magnitude of inhibition of GLP-1 secretion by hGPR17L (i.e., the combination of constitutive and agonist activation) was similar to the inhibition observed by somatostatin (SST), a known inhibitor of GLP-1 section [19], in control-transduced cells (Figure S2B)